Market Cap : 933.3 M | Enterprise Value : 860.33 M | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Equity is calculated as Net Income attributable to Common Stockholders divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Myovant Sciences's annualized net income attributable to common stockholders for the quarter that ended in Mar. 2022 was $-237.1 Mil. Myovant Sciences's average shareholder tangible equity for the quarter that ended in Mar. 2022 was $-452.9 Mil. Therefore, Myovant Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2022 was N/A%.
The historical rank and industry rank for Myovant Sciences's Return-on-Tangible-Equity or its related term are showing as below:
The historical data trend for Myovant Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Myovant Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Return-on-Tangible-Equity falls into.
Myovant Sciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2022 is calculated as
Return-on-Tangible-Equity | = | Net Income attributable to Common Stockholders | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(A: Mar. 2022 ) | (A: Mar. 2021 ) | (A: Mar. 2022 ) | |||||
= | Net Income attributable to Common Stockholders | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets ) | / count ) | |
(A: Mar. 2022 ) | (A: Mar. 2021 ) | (A: Mar. 2022 ) | |||||
= | -205.981 | / | ( (-353.965 | + | -473.477 ) | / 2 ) | |
= | -205.981 | / | -413.721 | ||||
= | N/A % |
Myovant Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2022 is calculated as
Return-on-Tangible-Equity | = | Net Income attributable to Common Stockholders | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(Q: Mar. 2022 ) | (Q: Dec. 2021 ) | (Q: Mar. 2022 ) | |||||
= | Net Income attributable to Common Stockholders | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets) | / count ) | |
(Q: Mar. 2022 ) | (Q: Dec. 2021 ) | (Q: Mar. 2022 ) | |||||
= | -237.14 | / | ( (-432.283 | + | -473.477) | / 2 ) | |
= | -237.14 | / | -452.88 | ||||
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income attributable to common stockholders of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data. Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Net income attributable to common stockholders is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Thank you for viewing the detailed overview of Myovant Sciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Potter Myrtle S | director | 10 FINDERNE AVE BRIDGEWATER NJ 08807 |
Guinan Mark | director | C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
Arjona Ferreira Juan Camilo | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Curran Terrie | director | C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Gulfo Adele M. | director | ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
Sebelius Kathleen | director | C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025 |
Lang Matthew | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 60 WALL STREET NEW YORK NY 10005 |
Seely Lynn | director, officer: Principal Executive Officer | 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107 |
Sablich Kim | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Nomura Hiroshi | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 |
Torti Frank | director | 2855 SAND HILL ROAD MENLO PARK CA 94025 |
From GuruFocus
Other Sources
By Seekingalpha 2021-06-02
By Seekingalpha 2021-07-28
By Seekingalpha 2022-01-26
By Zacks 2020-12-16
By Zacks 2021-10-26
By Zacks 2021-03-25
By Fool 2020-12-28
By Fool 2021-07-28
By Zacks 2021-05-10
By Zacks 2021-02-11
By Seekingalpha 2021-02-11
By Seekingalpha 2020-12-22
By Zacks 2021-04-13
By Zacks 2021-05-11